3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Neuroendocrine Tumors
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Oxaliplatin
21
pembrolizumab
17
Capecitabine
15
Nivolumab
13
Paclitaxel
12
Fluorouracil
12
Leucovorin
11
Docetaxel
10
atezolizumab
7
Trastuzumab
7
tislelizumab
5
Ramucirumab
5
durvalumab
4
Standard of Care
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
Cisplatin
4
Carboplatin
4
zolbetuximab
3
zimberelimab
3
apatinib
3
Specimen Handling
3
S 1 (combination)
3
Gemcitabine
3
Bevacizumab
3
trifluridine tipiracil drug combination
2
tremelimumab
2
trastuzumab deruxtecan
2
relatlimab
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Stomach Neoplasms
×
Radionuclide Imaging
×
Clear all
NCT06904365
2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
10 enrolled